Alivus Life Sciences's quarterly market cap
declined
from Sep. 2025 (₹113,989 Mil) to Dec. 2025 (₹112,449 Mil) but then
increased
from Dec. 2025 (₹112,449 Mil) to Mar. 2026 (₹119,385 Mil).
Alivus Life Sciences's annual market cap
increased
from Mar. 2024 (₹95,161 Mil) to Mar. 2025 (₹132,481 Mil) but then
declined
from Mar. 2025 (₹132,481 Mil) to Mar. 2026 (₹119,385 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Alivus Life Sciences's Enterprise Value for Today is ₹131,637 Mil.
Alivus Life Sciences (NSE:ALIVUS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Alivus Life Sciences Market Cap Related Terms
Alivus Life Sciences Market Cap Historical Data
* Premium members only.
The historical data trend for Alivus Life Sciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alivus Life Sciences Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Alivus Life Sciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Alivus Life Sciences's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alivus Life Sciences (NSE:ALIVUS) has a Market Cap of ₹139,217 Mil as of Jul. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Alivus Life Sciences and its competitors. According to the industry distribution chart, Alivus Life Sciences ranks #200 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 19.6%.
Is Alivus Life Sciences' Market Cap too high?
Alivus Life Sciences' current Market Cap is ₹139,217 Mil. Based on the distribution chart, Alivus Life Sciences ranks #200 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alivus Life Sciences has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alivus Life Sciences ranks #200 out of 1023 companies for Market Cap. This places Alivus Life Sciences in the top 20% of its industry — outperforming the majority of peers. The industry median Market Cap is 213.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 213.88, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Alivus Life Sciences and its competitors. For the Drug Manufacturers industry, the median Market Cap is 213.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alivus Life Sciences's current Market Cap is ₹139,217 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (NSE:ALIVUS) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,005.75, compared to a current price of ₹1,136.40 — trading 13% above its estimated fair value. The current Market Cap is ₹139,217 Mil. Alivus Life Sciences' overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Alivus Life Sciences (NSE:ALIVUS), the current Market Cap is ₹139,217 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?
Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued.
The current stock price of ₹1,136.40 is trading 13% above its estimated GF Value™ of ₹1,005.75.
GuruFocus considers Alivus Life Sciences to be Modestly Overvalued.
Key valuation signals for NSE:ALIVUS:
Market Cap: ₹139,217 Mil
GF Value™: ₹1,005.75 vs. price of ₹1,136.40 (13% above fair value)
No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
83GF Score
Get the complete analysis for NSE:ALIVUS
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALIVUS has been successfully added to your 
